iScience
Cure8 research brief
Why This Matters
Researchers engineered bispecific antibodies that block two inflammatory pathways (TL1A and IL-12/23p40) simultaneously, a strategy that could overcome limits of single-target therapies in IBD. The work is preclinical but relevant to future therapeutic options for IBD.
Who Should Pay Attention
Researchers studying IBD immunology or drug development, clinical investigators planning translational studies, and clinicians interested in emerging biologic strategies for IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This abstract reports preclinical development of two engineered bispecific antibodies (KA-4316 and KA-5817) that co-target TL1A and IL-12/23p40.
In vitro data show target binding and inhibition of downstream signaling; in vivo efficacy was tested in DSS colitis and humanized mouse models, and a half-life extension modification (YTE) was evaluated in FcRn-humanized mice. The source is an abstract-level report (iScience) and Cure8 did not independently verify full study details.
Keep In Mind
This is an abstract-level, preclinical study using engineered antibodies and humanized mouse models; results do not represent clinical trial findings. Further testing in clinical studies would be required to determine safety and efficacy in people with IBD.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationiScience
AuthorsLi X, Peng H, Hao F +3 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedOct 9, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Senkyunolide I Inhibits mtDNA‐cGAS‐STING Signaling in Macrophages via Targeting VDAC1 Oligomerization to Attenuate Ulcerative Colitis
The study identifies a new macrophage-driven immune pathway (VDAC1-mediated mtDNA release activating cGAS–STING) that contributes to ulcerative colitis in preclinical models and suggests a plant-derived compound (SEI)...
Molecular regulatory mechanism of TRPV4-mediated calcium-dependent 5-HT secretion from enterochromaffin cells and its involvement in ulcerative colitis
The study links a cellular signaling pathway that increases serotonin release from gut enterochromaffin cells to inflammation in a mouse model of ulcerative colitis. If confirmed, blocking TRPV4 could become a research...
New coumarin-piperazine derivatives alleviate inflammatory bowel diseases as IL-6 inhibitors by targeting NF-κB pathway
The study describes new small molecules that target IL‑6 and NF‑κB and showed anti-inflammatory effects in laboratory and mouse colitis models, signaling a potential early-stage drug-discovery direction relevant to IBD...